Evaxion A/S (NASDAQ:EVAX) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen downgraded shares of Evaxion A/S (NASDAQ:EVAX) from a buy rating to a hold rating in a research note released on Sunday morning.

EVAX has been the topic of several other reports. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a report on Monday, March 9th. Maxim Group initiated coverage on Evaxion A/S in a research note on Thursday, February 19th. They set a “buy” rating and a $10.00 target price for the company. Lake Street Capital decreased their price target on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research note on Friday, January 9th. Finally, JonesTrading began coverage on shares of Evaxion A/S in a research note on Tuesday, March 10th. They set a “buy” rating and a $10.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Evaxion A/S Stock Performance

Shares of EVAX stock opened at $3.91 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85. The company’s fifty day moving average price is $3.68 and its two-hundred day moving average price is $4.69. The firm has a market capitalization of $32.61 million, a P/E ratio of -2.96 and a beta of 0.28. Evaxion A/S has a 12 month low of $1.20 and a 12 month high of $12.15.

Institutional Investors Weigh In On Evaxion A/S

Several institutional investors and hedge funds have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. acquired a new position in Evaxion A/S in the fourth quarter worth $38,000. Wesbanco Bank Inc. bought a new stake in shares of Evaxion A/S during the 4th quarter valued at about $48,000. Finally, SmartHarvest Portfolios LLC bought a new stake in shares of Evaxion A/S during the 4th quarter valued at about $72,000. 11.04% of the stock is owned by institutional investors and hedge funds.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.